Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease

PURPOSE: Non-alcoholic fatty liver disease (NAFLD) is the main form of chronic liver disease in the world. Astragaloside IV (ASIV) has been tested in experimental models of different diseases. The purpose of this study was to evaluate the effect and protective mechanism of ASIV on NAFLD. METHODS: Li...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xiao-yu, Hong, Fen-Fang, Yang, Shu-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089473/
https://www.ncbi.nlm.nih.gov/pubmed/33953586
http://dx.doi.org/10.2147/DMSO.S304817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089473/
https://www.ncbi.nlm.nih.gov/pubmed/33953586
http://dx.doi.org/10.2147/DMSO.S304817

Ejemplares similares